Clinical Trials Logo

Filter by:
NCT ID: NCT04292184 Completed - Clinical trials for End Stage Renal Disease (ESRD)

Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation

Start date: March 21, 2021
Phase: Phase 1
Study type: Interventional

Kidneys retrieved from deceased donors will be randomized for conventional perfusion (University of Wisconsin: UW) with or without supplementation of thiosulfate, a major H2S metabolite, and transpl anted thereafter. Recipient's renal function will be assessed prospectively to determine if thiosulfate improves allograft function.

NCT ID: NCT04291898 Recruiting - Clinical trials for Atrial Septal Defect

Comparison of Devices for Atrial Septal Defects Closure: A Pilot Study

Trio-ASD
Start date: November 23, 2022
Phase: N/A
Study type: Interventional

This is a proposal, for the first time in Canada, to examine the comparative effectiveness of three commercially available devices (ASO, FSO, and GAO/GSO) for transcatheter closure of atrial septal defects (ASD) in adults using a pilot randomized controlled trial.

NCT ID: NCT04291690 Completed - Quality of Life Clinical Trials

The TARGET-EFT Randomized Clinical Trial

TARGET-EFT
Start date: March 5, 2020
Phase: N/A
Study type: Interventional

Randomized clinical trial to determine whether a multicomponent intervention will lead to improvements in mobility, self-care, mood, pain, and physical activity among frail and pre-frail older adults (as measured with the Essential Frailty Toolset; EFT) hospitalized for an acute cardiovascular illness.

NCT ID: NCT04291456 Terminated - Multiple Sclerosis Clinical Trials

Minocycline in MS: Confirmation of Benefit

MS
Start date: January 31, 2020
Phase: Phase 3
Study type: Interventional

This is an open-label, single-arm clinical trial. Trial participants will include men and women, aged 18-60 years who have had a first demyelinating event within the previous 180 days and who have brain magnetic resonance imaging (MRI) with at least two brain T2 lesions which are at least 3 mm in diameter, and at least one of which is ovoid or periventricular or infra-tentorial. Treatment with minocycline until the endpoint is reached or to a maximum of 24 months or until the last-enrolled participant reaches their 12 month visit.

NCT ID: NCT04291404 Completed - Clinical trials for Children Requiring IV Placement

Virtual Reality-based Distraction to Reduce Distress in the Pediatric Emergency Department

Start date: September 28, 2020
Phase: N/A
Study type: Interventional

Needle procedures, such as intravenous (IV) insertions, are among the most commonly performed procedures for children needing medical care. IV insertions are often a painful and stressful experience for both children and their parents/ caregivers. Pediatric pain and distress that is not adequately treated may lead to a frightened and uncooperative child, repeated IV attempts and overall frustration with care for the family and clinical team. Distraction therapy is a common psychological strategy which involves engaging children in a cognitive task or activity in order to divert attention away from painful stimuli. Given children's growing enthusiasm for novel technology, the investigators propose that an immersive virtual reality (VR) experience may provide an effective means of distraction for children undergoing IV insertions.

NCT ID: NCT04291391 Completed - Obesity Clinical Trials

The Alberta NutrIMM Study - Nutrition and Immunity

NutrIMM
Start date: September 1, 2019
Phase: N/A
Study type: Interventional

This study will investigate the effect of body weight, diet, and high blood sugar levels, under controlled feeding conditions, on immune function in individuals with and without obesity. This study will be a non-randomized, four-arm parallel group, clinical trial under controlled feeding conditions (4-week nutritional intervention using a North American-type diet). A sample size of n=128 participants will be allocated into one of the following groups: - Individuals without obesity and normoglycemia (NG) (Lean-NG) - Individuals with obesity and normoglycemia (Obese-NG) - Individuals with obesity and glucose intolerance (GI) (Obese-GI) - Individuals with obesity and type 2 diabetes (T2D) (Obese-T2D) The following outcomes will be analyzed: - Immune cell function (ex-vivo cytokine production after stimulation with mitogen and T cell proliferation); - Immune cell phenotypes; - Systemic inflammation (C-reactive protein and plasma cytokines); - Glucose, insulin, glycated hemoglobin (HbA1c), and lipids; - Fatty acids and phospholipds composition in plasma and red blood cells membrane.

NCT ID: NCT04291352 Recruiting - Thalassemia Major Clinical Trials

Thalassemic Iron Overload Cardiomyopathy is Ameliorated by Taurine Supplementation

TICATS
Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Hypothesis: Taurine, in combination with standard iron chelation therapy, is more effective than chelation therapy alone in reducing cardiac iron overload, oxidative stress and cardiac damage in β-Thalassemia. Protocol: Sixty subjects with transfusion dependent β-Thalassemia receiving deferasirox iron chelation therapy will be recruited and randomized in a 1:1 ratio to either (1) placebo and continuation of their iron chelation or (2) a combination of iron chelation plus taurine. Transfusion and safety visits will be scheduled monthly with clinical/biochemical assessment visits every three months. The efficacy of taurine combined with standard chelation therapy will be assessed at baseline and 12 months posttreatment by both cardiac T2*MRI, and cardiac function. The recruitment period is projected to be 12 months from initiation.

NCT ID: NCT04291235 Not yet recruiting - Acute Brain Injury Clinical Trials

The NEUROlogically-impaired Extubation Timing Trial (NEURO-ETT)

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

This trial in brain-injured patients will test which of the following will lead to better patient outcomes: (1) an airway management pathway consisting of daily assessments and removal of the breathing tube as soon as patients can breathe on their own and appear able to protect their airway; versus (2) the usual treatment patients would have received if they were not enrolled in this trial.

NCT ID: NCT04291209 Recruiting - Clinical trials for Ototoxic Hearing Loss

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Start date: February 26, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Although many intratympanic agents have been attempted, N-Acetylcysteine (NAC) appears to be the most promising and is a powerful, commonly used anti-oxidant. The goal of this prospective phase 2 randomized controlled trial is to determine the optimal dosage and effectiveness of intratympanic NAC injection in reducing hearing loss in head & neck cancer patients receiving cisplatin chemotherapy with curative intent.

NCT ID: NCT04291196 Recruiting - Depression Clinical Trials

Virtual Reality to Reduce Pre-procedure Anxiety Prior ECT

PERFECT-VR
Start date: November 27, 2020
Phase: N/A
Study type: Interventional

Lack of patient knowledge about ECT (electroconvulsive therapy) is a leading cause of treatment fear with 60% of ECT patients reporting high levels of anxiety. The purpose of this study is to determine if using Virtual Reality (VR) to allow patients' to experience a virtual ECT education session before treatment is useful in lowering treatment anxiety and increasing knowledge about ECT if compared to standard treatment. In addition, measuring heart rate and blood pressure levels before ECT treatment will allow us to assess changes in anxiety levels. Individuals who choose to participate will be placed (participant will have a 50% chance to be placed in either group) to view either a virtual reality video to experience a virtual ECT session, or to receive standard preparation, i.e. a discussion with a psychiatrist. Before and after this session participants will be asked to complete a measurement of their anxiety level and knowledge about ECT (ECT Attitude & Knowledge Questionnaire). Just before ECT treatment, blood pressure, heart rate and anxiety level will be measured. Participants will also complete cognitive and depression assessments. This study will help to develop a relationship between healthcare providers and patients and their families to help with education before ECT treatment.